Johnson & Johnson completed the acquisition of Firefly Bio for $1 billion in cash and entered into a strategic collaboration with Sail Biomedicines, including an equity investment and an exclusive option to acquire Sail for $2.58 billion. These transactions are expected to dilute adjusted operational EPS and adjusted EPS by approximately $0.64 in 2026 ($0.46 from Firefly, $0.18 from Sail) and $1.36 in 2027. Consequently, the company updated its full-year 2026 guidance, lowering the midpoint for adjusted operational EPS to $10.94 (from $11.58), adjusted sales growth to a 6.2%-6.8% range, and estimated reported sales to a $100.8B-$101.4B range. Johnson & Johnson is a diversified healthcare company engaged in the research, development, manufacture, and sale of products in the pharmaceutical, medical devices, and consumer health sectors.

Johnson & Johnson announced a comprehensive resolution agreement for its remaining ovarian talc litigation, conditioned on at least 95% participation by claimants. The company committed $5.5 billion to settle these claims through per-claim payments, with the first tranche capped at $3 billion in 2027 and no further payments due before 2028. This settlement follows a favorable Multi-District Litigation court ruling on specific causation that undermined the plaintiffs' scientific evidence. Johnson & Johnson operates as a global healthcare company developing innovative medicines, medical devices, and consumer health products.

Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, a 6.6% increase over the prior year, with adjusted EPS of $2.90. The company raised its full-year 2026 guidance, increasing estimated reported sales to a midpoint of $101.1 billion and adjusted EPS guidance by $0.13 to a midpoint of $11.68. Key growth drivers included the Innovative Medicine segment, specifically oncology products like Darzalex and Carvykti. The company also announced a new supply chain restructuring program in the Innovative Medicine segment with estimated costs between $650 million and $750 million to be completed by 2029. The company operates in the healthcare industry, specializing in innovative medicine and medical technology.

Johnson & Johnson shareholders elected all 12 director nominees and approved executive compensation and the appointment of PricewaterhouseCoopers LLP as auditor at the company's 2026 Annual Meeting. A shareholder proposal to mandate an independent board chair was defeated, receiving 406,353,048 votes in favor and 1,326,857,173 votes against.

Johnson & Johnson has elected John Morikis to its Board of Directors, effective September 8, 2025. Mr. Morikis, the former Executive Chairman, President, and CEO of The Sherwin-Williams Company, will also serve on the company's Audit Committee and Compensation & Benefits Committee.